Inhaler assessment in COPD patients

Chronic Obstructive Pulmonary Disease, 2009. Statistics Canada: 2011. Available: www.statcan.gc.ca/pub/82-625-x/2010002/article/11273-eng.htm (accessed Dec. 5, 2015).

The Lung Association. Canadian Lung Association: 2014. Available: www.lung.ca/lung-health/lung-disease/copd/medication (accessed Dec. 5, 2015).

Fink JB Colice GL Hodder R. Inhaler devices for patients with COPD. COPD 2013;10(4):523-35.

Decramer M Agusti AG Bourbea J . Global strategy for the diagnosis, management and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2015. Available: www.goldcopd.org/ (accessed Dec. 5, 2015).

Vincken W Dekhuijzen PR Barnes P ; ADMIT Group. The ADMIT series: issues in inhalation therapy. 4) How to choose inhaler devices for the treatment of COPD. Prim Care Respir J 2010;19(1):10-20.

Yawn BP Colice GL Hodder R. Practical aspects of inhaler use in the management of chronic obstructive pulmonary disease in the primary care setting. Int J Chron Obstruct Pulmon Dis 2012;7:495-502.

Fromer L Goodwin E Walsh J. Customizing inhaled therapy to meet the needs of COPD patients. Postgrad Med 2010;122(2):83-93.

Batterink J Dahri K Aulakh A Rempel C. Evaluation of the use of inhaled medications by hospital inpatients with chronic obstructive pulmonary disease. Can J Hosp Pharm 2012;65(2):111-8.

Barrons R Pegram A Borries A. Inhaler device selection: special considerations in elderly patients with chronic obstructive pulmonary disease. Am J Health Syst Pharm 2011;68(13):1221-32.

The Drug Product Database. Health Canada: 2015. Available: www.hc-sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php (accessed Dec. 5, 2015).

Nobles J Hutchison AM. Potential problems and solutions with inhaler use in elderly COPD patients. Consult Pharm 2014;29(11):753-6.

Osterberg L Blaschke T. Adherence to medication. N Engl J Med 2005:353(5):487-97.

Novartis Pharmaceuticals Canada Inc. Formoterol fumarate aerolizer product monograph. Dorval (QC): Novartis Pharmaceuticals Canada Inc.; 2015.

Novartis Pharmaceuticals Canada Inc. Glycopyrronium bromide breezehaler product monograph. Dorval (QC): Novartis Pharmaceuticals Canada Inc.; 2015.

Novartis Pharmaceuticals Canada Inc. Indacaterol maleate breezhaler product monograph. Dorval (QC): Novartis Pharmaceuticals Canada Inc.; 2015.

Novartis Pharmaceuticals Canada Inc. Indacaterol maleate and glycopyrronium bromide breezhaler product monograph. Dorval (QC): Novartis Pharmaceuticals Canada Inc.; 2013.

GlaxoSmithKline, Inc. Salmeterol xinafoate/fluticasone propionate diskus product monograph. Mississauga (ON): GlaxoSmithKline, Inc.; 2014.

GlaxoSmithKline, Inc. Salmeterol xinafoate diskhaler product monograph. Mississauga (ON): GlaxoSmithKline, Inc.; 2014.

GlaxoSmithKline, Inc. Fluticasone furoate and vilanterol trifenatate ellipta product monograph. Mississauga (ON): GlaxoSmithKline, Inc.; 2015.

GlaxoSmithKline, Inc. Umeclidinium bromide ellipta product monograph. Mississauga (ON): GlaxoSmithKline, Inc.; 2015.

GlaxoSmithKline, Inc. Umeclidinium bromide and vilanterol trifenatate ellipta product monograph. Mississauga (ON): GlaxoSmithKline, Inc.; 2014.

AstraZeneca Canada Inc. Aclidinium bromide/formoterol fumarate dehydrate genuair product monograph. Mississauga (ON): GlaxoSmithKline, Inc.; 2015.

AstraZeneca Canada Inc. Aclidinium bromide genuair product monograph. Mississauga (ON): AstraZeneca Canada Inc.; 2015.

Boehringer Ingelheim Canada Ltd. Tiotropium bromide monohydrate handihaler product monograph. Burlington (ON): Boehringer Ingelheim Canada Ltd.; 2015.

Boehringer Ingelheim Canada Ltd. Ipratropium bromide HFA product monograph. Burlington (ON): Boehringer Ingelheim Canada Ltd.; 2010.

Sanis Health Inc. Salbutamol HFA product monograph. Dieppe (NB): Sanis Health Inc.; 2014.

Pharmel Inc. Salbutamol sulfate respirator solution product monograph. Montreal (QC): Pharmel Inc.; 2004.

Boehringer Ingelheim Canada Ltd. Ipratropium bromide and salbutamol Respimat product monograph. Burlington (ON): Boehringer Ingelheim Canada Ltd.; 2014.

Boehringer Ingelheim Canada Ltd. Tiotropium and olodaterol Respimat product monograph. Burlington (ON): Boehringer Ingelheim Canada Ltd.; 2015.

Boehringer Ingelheim Canada Ltd. Tiotropium bromide monohydrate Respimat product monograph. Burlington (ON): Boehringer Ingelheim Canada Ltd.; 2015.

The Lung Association of Saskatchewan. Inhalers. 2015. Available: https://sk.lung.ca/lung-diseases/inhalers (accessed Dec. 16, 2015).

Prime D De Backer W Hamilton M . Comparison of inhalation profiles through a novel dry powder inhaler nDPI and lung function measurements for healthy subjects, asthma and chronic obstructive pulmonary disease (COPD) patients. Am J Resp Crit Care Med 2012;185:A2941.

Magnussen H Watz H Zimmermann I . Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD. Respir Med 2009;103(12):1832-7.

Ram FS Carvallho CR White J. Clinical effectiveness of the Respimat inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices. Int J Chron Obstruct Pulmon Dis 2011;6:129-39.

Pavkov R Mueller S Fiebich K . Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr Med Res Opin 2010;26(11):2527-33.

Given J Taveras H Iverson H Lepore M. Prospective, open-label assessment of albuterol sulfate hydrofluoroalkane metered-dose inhaler with new integrated dose counter. Allergy Asthma Proc 2013;34(1):42-51.

AstraZeneca Canada Inc. Budesonide/formoterol fumarate dehydrate turbuhaler product monograph. Mississauga (ON): AstraZeneca Canada Inc.; 2012.